Tanke Biosciences Corporation

Symbol: TNBI

PNK

0.04

USD

Market price today

  • -11.7847

    P/E Ratio

  • 0.0720

    PEG Ratio

  • 0.53M

    MRK Cap

  • 0.00%

    DIV Yield

Tanke Biosciences Corporation (TNBI) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-1.04%

Return on Equity

0.99%

Return on Capital Employed

0.81%

Company general description and statistics

Sector: Financial Services
Industry: Shell Companies
CEO:Ms. Caren Currier
Full-time employees:130
City:Guangzhou
Address:East Tower of Hui Hao Building
IPO:2012-05-11
CIK:

Tanke Biosciences Corporation, through its subsidiaries, develops, produces, markets, and sells animal nutrition and feed additive products. It operates in four segments: Organic Trace Mineral Additives, Functional Regulation Additives, Herbal Medicinal Additives, and Other. The company offers organic trace mineral additives under the Qili brand name; feed acidifiers, which are used to prevent microbial degradation of raw materials or finished feeds under the Qilicid name; seasonings; flavor enhancers that are used as the agent in the production of blended feed under the Tankeball name; and herbal medicinal additives blended with feed products under the Extra-Health, Qilimix, and Recoccider names. It also produces and markets multiple trace mineral premix products for livestock and poultry under the Qilimix name. In addition, the company provides natural sweeteners and attractants for use with feed for pigs, piglets, fish, and other aquatic animals under the Tankeball name; and water soluble organic multi-vitamin electrolyte, which is fed to animals through dissolving it in drinking water for the animals to consume. It serves mid-to-large sized feed product factories, large scale feed producers, and farmers. The company sells its products primarily in the People's Republic of China, Southeast Asia, and Latin America. Tanke Biosciences Corporation was founded in 1989 and is headquartered in Guangzhou, the People's Republic of China.

Return on Investments

The company's asset efficiency, represented by a robust -1.036% return, is a testament to Tanke Biosciences Corporation's adeptness in optimizing resource deployment. Tanke Biosciences Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.989%. Furthermore, the proficiency of Tanke Biosciences Corporation in capital utilization is underscored by a remarkable 0.808% return on capital employed.

Liquidity Ratios

Analyzing TNBI liquidity ratios reveals its financial health of the firm. The current ratio of 1.61% gauges short-term asset coverage for liabilities. The quick ratio (1.61%) assesses immediate liquidity, while the cash ratio (1.61%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio1.61%
Quick Ratio1.61%
Cash Ratio1.61%

Profitability Ratios

The net income per EBT, 100.00%, and the EBT per EBIT, 92.73%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Net Income per EBT100.00%
EBT per EBIT92.73%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.02, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding2
Days of Payables Outstanding472
Payables Turnover0.77

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 202.44%, highlights its total liabilities relative to assets. With a debt-equity ratio of -1.46, we discern the balance between debt and equity financing. An interest coverage of -1.45 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio202.44%
Debt Equity Ratio-1.46
Total Debt to Capitalization315.71%
Interest Coverage-1.45
Cash Flow to Debt Ratio-0.53
Company Equity Multiplier-0.72

Growth Ratios

EBIT growth, 26.54%, and operating income growth, 26.54%, offer insights into operational profitability progression. The net income growth, 15.92%, showcases bottom-line expansion, and the EPS growth, 50.63%, measures the growth in earnings per share.

cards.indicatorcards.value
EBIT Growth26.54%
Operating Income Growth26.54%
Net Income Growth15.92%
EPS Growth50.63%
EPS Diluted Growth50.63%
Weighted Average Shares Growth69.22%
Weighted Average Shares Diluted Growth69.22%
Operating Cash Flow Growth-26.17%
Free Cash Flow Growth-26.17%
10-Year Shareholders Equity Growth per Share-553.07%
5-Year Shareholders Equity Growth per Share-553.07%
3-Year Shareholders Equity Growth per Share-553.07%
Asset Growth845.01%
Book Value per Share Growth35.86%
Debt Growth164.02%
SGA Expenses Growth-33.17%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,302,124.839, captures the company's total value, considering both debt and equity. Income quality, 0.90, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value3,302,124.839
Income Quality0.90
Intangibles to Total Assets34.70%
Graham Number0.02
Return on Tangible Assets-182.75%
Graham Net Net-0.01
Working Capital-162,155
Tangible Asset Value-119,655
Net Current Asset Value-162,155
Invested Capital-1
Average Payables5,500
Days Payables Outstanding472
ROIC-212.34%
ROE0.86%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -8.83, and the price to book ratio, -8.83, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -7.14, and price to operating cash flows, -11.31, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-8.83
Price to Book Ratio-8.83
Price Cash Flow Ratio-11.31
Price Earnings to Growth Ratio0.07
Enterprise Value Multiple-5.75
Price Fair Value-8.83
Price to Operating Cash Flow Ratio-11.31
Price to Free Cash Flows Ratio-7.14
Price to Tangible Book Ratio-33.09
Enterprise Value Over EBITDA-38.55
EV to Operating Cash Flow-44.23
Earnings Yield-2.61%
Free Cash Flow Yield-2.36%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Tanke Biosciences Corporation (TNBI) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -11.785 in 2024.

What is the ticker symbol of Tanke Biosciences Corporation stock?

The ticker symbol of Tanke Biosciences Corporation stock is TNBI.

What is company IPO date?

IPO date of Tanke Biosciences Corporation is 2012-05-11.

What is company current share price?

Current share price is 0.040 USD.

What is stock market cap today?

The market cap of stock today is 532960.000.

What is PEG ratio in 2024?

The current 0.072 is 0.072 in 2024.

What is the number of employees in 2024?

In 2024 the company has 130.